# Advisor Review - GPT-5.4 (R2)

**Role:** Academic advisor checking for fatal errors
**Model:** openai/gpt-5.4
**Paper:** paper.pdf
**Timestamp:** 2026-03-10T15:30:27.006335
**Route:** OpenRouter + LaTeX
**Paper Hash:** 2f7bf1fc6e3cc9a9
**Tokens:** 21581 in / 2503 out
**Response SHA256:** 340b6e554d09f8d5

---

FATAL ERROR 1: Internal Consistency  
  Location: Section 3.4 “FDA 510(k) Clearance Database”; Table \ref{tab:summary}, Panel C; Appendix A, subsection “FDA openFDA 510(k) Database”  
  Error: The paper reports “174,263 clearance records spanning our entire sample period” (2015–2025), but Table \ref{tab:summary} Panel C reports annual FDA 510(k) counts of about 3,014/year in 2015–2020 and 3,187/year in 2021–2025. Over 11 years, those annual counts imply roughly 34,000 total clearances, not 174,263. These numbers cannot both be true. This indicates a data construction or reporting error in the FDA benchmark series.  
  Fix: Reconcile the FDA extraction and aggregation. Either:
  - correct the total record count if the usable 2015–2025 sample is ~34,000 observations, or
  - explain that 174,263 is a broader raw extract outside the study window and report the filtered 2015–2025 analytic sample separately.
  Then update all text and tables so the total record count matches the annual counts shown.

FATAL ERROR 2: Internal Consistency  
  Location: Appendix F, “Standardized Effect Sizes,” note lines beginning “Data:” and “Sample:”  
  Error: Appendix F states the data/sample are “6 EU countries + Turkey” with “N = 418 (DiD), N = 528 (DDD).” This conflicts with the main data description, which says the preferred DiD sample uses EU countries only and that control sectors are available in up to 16 EU countries, producing 418 observations after fixed-effects restrictions. Thus the Appendix F sample description is inconsistent with the actual regression sample behind Table \ref{tab:main_results} column (2).  
  Fix: Rewrite Appendix F to match the main sample construction exactly. For example, state that:
  - the preferred DiD uses the EU-only panel with broader control-sector coverage (not just the 6 treated countries),
  - the DDD adds Turkey plus the additional non-EU control-sector countries listed earlier if they are indeed included,
  - and the reported N corresponds to those exact samples.

ADVISOR VERDICT: FAIL